Company interested in acquiring novel product for orphan tumour type in a tight turnaround window, but pricing a large uncertainty

Examined pricing and reimbursement analogues of therapeutics for similar- prevalence conditions. Conducted a regression analysis that predicted the likely reimbursed price for a novel oncologic given a specific prevalence. Applied this, as well as early cost-utility analysis and payer interviews to support a commercially-viable price for the deal

All work was completed in time for Board meeting and approval, resulting in acquisition of the asset